alanine/bröstcancer

Länken sparas på Urklipp

Välj sorteringstyp

14 resultat

A Study to Evaluate Camrelizumab in Combination With Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage III Gastric Cancer

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

1. Test population: Patients with stage III gastric cancer confirmed by postoperative pathology 2. Sample size calculation: single arm design was used in this study, and the main outcome was progression free survival. In this study, PD-L1 + CPS ≥ 10% / MSI-H + / EB +, the sample size was estimated

S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

PRIMARY OBJECTIVES: I. To assess whether prophylactic beta blocker therapy with carvedilol compared with no intervention reduces the risk of subsequent cardiac dysfunction in patients with metastatic breast cancer receiving trastuzumab?based HER-2 targeted therapy. SECONDARY OBJECTIVES: I. To assess

Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust) Versus Herceptin® in Breast Cancer

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

This is A Phase III, randomized, two-armed, patient-outcome assessor-data analyzer blinded, parallel active controlled non-Inferiority clinical trial study to evaluate efficacy and safety of AryoTrust (Aryogen Trastuzumab) in comparison to Herceptin® (Genentech/Roche) in patients with Human

Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

Inclusion criteria: 1. Patients with stage IV breast cancer with metastases demonstrated by appropriate imaging techniques 2. Histologically or cytologically confirmed tumor 3. Age of 18 years or more 4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2 5. Patients have failed,

Ribociclib and Bicalutamide in AR+ TNBC

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

OUTLINE: This is a multi-center study. INVESTIGATIONAL TREATMENT: - bicalutamide - 150mg po daily D1 - D28 (Cycle = 28 days) - ribociclib po daily D1 - D21 of 28 day cycle PHASE I SAFETY RUN-IN COHORT: The maximum tolerated dose (MTD) of bicalutamide in combination with ribociclib will be determined

Compassionate Single Subject Use of FG-3019 (FibroGen) in Locally Advanced, Unresectable Pancreatic Cancer

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

The FG-3019 treatment will be administered over a 28-day cycle: - Dose: 35 mg/kg - Route: IV over one hour following completion of gemcitabine infusion - Schedule: - Days 1, 8, and 15 - Please note that Day 8 infusion will on be completed during the first treatment cycle On Drug Evaluation The

Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

1. Introduction to investigational treatment(s) and other study treatment(s) 1.1 Overview of gemcitabine Gemcitabine (29,29-difluoro 29-deoxycytidine, dFdC) which developed from cytosine arabinoside (Ara-C) is an nucleoside analog used as chemotherapy. It was intended as an antiviral drug in

Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

OUTLINE: This is a multi-center trial. INVESTIGATIONAL TREATMENT: - Palbociclib 125 mg will be administered orally once daily on days 1-21 (D1-D21) of each 28-day cycle. Subjects will not take palbociclib on D22-D28. - Tamoxifen 20 mg will be administered orally once daily for every day of the

Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

OUTLINE: This is a multi-center trial. SEQUENCING: DNA from archived tumor samples collected at the time of surgery (residual disease post neoadjuvant chemotherapy) will be extracted and sequenced. The resulting sequencing data will be interrogated for known genomic drivers of sensitivity or

Biomarkers in Exhaled Breath Condensates in Acute Lung Injury: Early Detection and Outcome Predictors

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are the leading causes of mortality and morbidity in the intensive care unit (ICU). The causes of ALI/ARDS differ from patient to patient, including sepsis, aspiration, systemic inflammation, trauma, blood transfusion, etc. With

Physician Liver Function Test (LFT) Monitoring for Tykerb Pts

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

OUTLINE: This is a multi-center study. Safety Run-in will be for the first 12 patients on study only (6 in cohort 1 and 6 in cohort 2). Patients in the safety run will be included in the efficacy analysis on intent to treat basis: Cisplatin 75 mg/m2 IV D1 every 3 weeks x 4 cycles; Rucaparib 16-30 mg

Metronomic Chemotherapy With Tegafur/Uracil for Head and Neck Squamous Cell Carcinoma

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

Head and neck squamous cell carcinoma (HNSCC) (excluding nasopharyngeal cancer) accounts for 4% to 5% of the cancer incidence in Taiwan.1 Localized disease is curable by surgery and irradiation. Two-thirds of patients present with advanced stages of the disease (stage III and IV), and are treated

Lonafarnib in Metastatic Breast Cancer

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

OUTLINE: This is a multi-center study Patients will be treated with lonafarnib 200 mg PO BID daily on days 1-21 of every 21-day cycle until progression of disease, unacceptable toxicity, or investigator's discretion. 1 Cycle = 21 days of lonafarnib (plus the time required to recover from toxicity if

Gå med på vår
facebook-sida

Herbal & Natural Medicine

Den mest kompletta databasen med medicinska örter som stöds av vetenskapen

Fungerar på 55 språk
Växtbaserade botemedel som stöds av vetenskap
Örter igenkänning av bild
Interaktiv GPS-karta - märka örter på plats (kommer snart)
Läs vetenskapliga publikationer relaterade till din sökning
Sök efter medicinska örter efter deras effekter
Organisera dina intressen och håll dig uppdaterad med nyheterna, kliniska prövningar och patent

Skriv ett symptom eller en sjukdom och läs om örter som kan hjälpa, skriv en ört och se sjukdomar och symtom den används mot.
* All information baseras på publicerad vetenskaplig forskning